ClearPoint Neuro price target raised to $20 from $15 at B. Riley

B. Riley analyst Kyle Bauser raised the firm’s price target on ClearPoint Neuro (CLPT) to $20 from $15 and keeps a Buy rating on the shares. ClearPoint Neuro on Monday announced FDA clearance of its Version 3.0 Navigation Software, which expands the platform’s capabilities to include CT-guided procedures in the operating room, in addition to its existing MRI-guided functionality, the analyst tells investors in a research note. This new functionality will streamline workflows for healthcare providers ahead of unlocking new patient populations treated with cell and gene therapies across the company’s more than 50 global biopharma partners, the firm says.